DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Qutenza (Capsaicin) - Summary

 
 



QUTENZA SUMMARY

Qutenza (capsaicin) 8% patch contains capsaicin in a localized dermal delivery system. The capsaicin in Qutenza is a synthetic equivalent of the naturally occurring compound found in chili peppers. Capsaicin is soluble in alcohol, acetone, and ethyl acetate and very slightly soluble in water. Qutenza is a single-use patch stored in a foil pouch. Each Qutenza patch is 14 cm x 20 cm (280 cm2) and consists of a polyester backing film coated with a drug-containing silicone adhesive mixture, and covered with a removable polyester release liner. The backing film is imprinted with "capsaicin 8%". Each Qutenza patch contains a total of 179 mg of capsaicin (8% in adhesive, 80 mg per gram of adhesive) or 640 micrograms (mcg) of capsaicin per square cm of patch.

Qutenza is indicated for the management of neuropathic pain associated with postherpetic neuralgia.


See all Qutenza indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Qutenza (Capsaicin)

Could chili peppers reduce the risk of colorectal cancer?
Source: Colorectal Cancer News From Medical News Today [2014.08.04]
A study from UC-San Diego School of Medicine found that mice fed capsaicin - the active ingredient in chili peppers - had lower tumor growth in the gut and increased lifespan.

Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds
Source: MedicineNet Chronic Pain Specialty [2014.08.22]
Title: Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds
Category: Health News
Created: 8/22/2014 9:36:00 AM
Last Editorial Review: 8/22/2014 12:00:00 AM

U.S. to Tighten Access to Certain Narcotic Painkillers
Source: MedicineNet Drug Abuse Specialty [2014.08.22]
Title: U.S. to Tighten Access to Certain Narcotic Painkillers
Category: Health News
Created: 8/21/2014 4:36:00 PM
Last Editorial Review: 8/22/2014 12:00:00 AM

Treating pain by blocking the 'chili-pepper receptor'
Source: Biology / Biochemistry News From Medical News Today [2014.08.21]
Biting into a chili pepper causes a burning spiciness that is irresistible to some, but intolerable to others.

IBS - why pain relief drugs don't work
Source: GastroIntestinal / Gastroenterology News From Medical News Today [2014.08.21]
New research from the University of Adelaide is the first in the world to explain why people with irritable bowel syndrome - also known as IBS - may not get relief from pain medications.

more news >>

Published Studies Related to Qutenza (Capsaicin)

Topical capsaicin (low concentration) for chronic neuropathic pain in adults. [2012]
CONCLUSIONS: There were insufficient data to draw any conclusions about

Capsaicin instillation for postoperative pain following total knee arthroplasty: a preliminary report of a randomized, double-blind, parallel-group, placebo-controlled, multicentre trial. [2011.12.01]
BACKGROUND: Pain following total knee arthroplasty (TKA) interferes with rehabilitation. Capsaicin applied in high concentration to nociceptors can cause relatively selective C-fibre desensitization for a period of weeks to months. Resultant long-lasting analgesia might facilitate rehabilitation. OBJECTIVE: The objective of this study was to determine if direct instillation of a high-concentration capsaicin preparation into the wound following TKA would provide pain relief, improve physical functioning and rehabilitation, and reduce opioid requirements... CONCLUSION: Despite having higher BMIs, patients in the capsaicin group achieved comparable or better pain scores with significantly less opioid use in the first 3 postoperative days. They also had less pruritus, which may have been a consequence of the opioid-sparing effect. The effects of capsaicin with respect to function, however, appeared to be longer lasting, with improved active ROM reported at 14 days.

A randomized, double-blind, parallel trial comparing capsaicin nasal spray with placebo in subjects with a significant component of nonallergic rhinitis. [2011.08]
OBJECTIVE: To investigate the efficacy and safety of ICX72 or Sinus Buster, a proprietary homeopathic preparation of Capsicum annum and Eucalyptol, versus placebo administered continuously over 2 weeks in subjects with a significant component of nonallergic rhinitis (NAR)... CONCLUSION: This is the first controlled trial demonstrating intranasal capsaicin, when used continuously over 2 weeks, rapidly and safely improves symptoms in rhinitis subjects with a significant NAR component. Copyright (c) 2011 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Self-reported sleep duration associated with distraction analgesia, hyperemia, and secondary hyperalgesia in the heat-capsaicin nociceptive model. [2011.07]
Although sleep deprivation is known to heighten pain sensitivity, the mechanisms by which sleep modifies nociception are largely unknown. Few studies of sleep-pain interactions have utilized quantitative sensory testing models that implicate specific underlying physiologic mechanisms...

Effects of lidocaine patch on intradermal capsaicin-induced pain: a double-blind, controlled trial. [2011.03]
This study evaluated the effects of topical lidocaine on skin sensation and on intradermal capsaicin-induced pain and hyperalgesia. A randomized, double-blinded, placebo controlled methodology was used...

more studies >>

Clinical Trials Related to Qutenza (Capsaicin)

The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain [Recruiting]
Subcutaneous treprostinil (Remodulin) is effective therapy for pulmonary arterial hypertension, a life threatening disease of the lung blood vessels. Unfortunately, treprostinil is irritating to the skin and many patients experience intense pain at the infusion site for the first 7-10 days after placing a new subcutaneous infusion site.

Qutenza is an FDA approved formulation of 8% capsaicin that is approved for the treatment of post-herpetic neuralgia, a painful skin condition. The investigators hypothesize that pretreatment of an area of skin with Qutenza would decrease the pain associated with a new treprostinil infusion site. The investigators hope that Qutenza will decrease both the intensity of the pain and the duration of the pain after patients place a new treprostinil infusion site.

In this initial study, the investigators will provide Qutenza in open-label, unblinded fashion and ask patients to rate their pain using a diary tool with which they are already comfortable.

Method of Pre-treatment for Application of QUTENZA Capsaicin 8% Patch [Recruiting]
The Summary of product characteristics (SmPC) for QUTENZA advises that topical anaesthetic is applied prior to the application of QUTENZA. This is a multi-center, randomized, assessor-blinded study which will investigate the use of an oral analgesic as an alternative form of pre-treatment for QUTENZA.

Acute Response Capsaicin Flare Study [Recruiting]
Prior to administering PF-04427429 to patients we wish to increase the understanding of functional effects associated with calcitonin gene related peptide (CGRP) pathways. This study will examine whether it is possible for a single dose of PF-04427429 to acutely attenuate a capsaicin induced flare response.

Safety and Effectiveness of Repeated Administration of QUTENZA Patches for Treatment of Pain Caused by Nerve Damage [Recruiting]
In this study all patients will be treated with the same medicine, the QUTENZA patch. Subjects will receive up to 6 QUTENZA patch applications over 12 months.

Qutenza«-Remodulin« in Pulmonary Arterial Hypertension Patients [Recruiting]
The investigators hypothesise that pre-application of Qutenza« patches to the skin may reduce pain at the site of Remodulin« SC infusion (sited 1 to 2 weeks later at the site of Qutenza pre-application), in which case it would greatly improve the quality of life of the patients, and enable many more to continue with this treatment. It may also provide new information to support the use of Qutenza« patches for preventing and reducing pain produced by inflammation.

The present study will explore the efficacy of single applications of Qutenza® (capsaicin 8% patch) in reducing site pain caused by continuous SC infusion of Remodulin®, in pulmonary arterial hypertension patients, as assessed by changes in subjective pain rating score and/or pain and sensory testing.

more trials >>

Reports of Suspected Qutenza (Capsaicin) Side Effects

Application Site Pain (26)Application Site Erythema (15)Condition Aggravated (8)Hypertension (7)Neuralgia (7)Pain (6)Application Site Swelling (5)Application Site Pruritus (5)Dizziness (5)Application Site Vesicles (5)more >>


Page last updated: 2014-08-22

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014